Caplacizumab

Red

Brand Name(s):Cablivi

Indication:Thrombotic thrombocytopenic purpura (acquired) in conjunction with plasma exchange and immunosuppression.

Rationale:1,2

Considered:Jun-19

Review Date:Jan-26

Comments:
NICE TA677 recommends caplacizumab, with plasma exchange and immunosuppression, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg